Ovarian Ageing: From Biological Constraint To Emerging Therapeutic Frontier
As women age, their reproductive potential naturally declines due to a process known as ovarian aging. This involves a gradual reduction in both the number of eggs available and their overall quality. This decline is driven by two main factors: the exhaustion of the primordial follicle pool, which is the reserve of immature eggs, and a decrease in the eggs’ ability to develop properly.
At a deeper level, this aging process is linked to a complex network of molecular changes. These include problems with mitochondria, which are the energy-producing parts of cells, metabolic imbalances, instability in genetic material, cells entering a state where they stop dividing (cellular senescence), and inflammation within the ovarian environment.
Currently, doctors assess ovarian aging using markers like anti-Müllerian hormone (AMH) and antral follicle count (AFC). However, these tests mainly indicate the quantity of remaining eggs rather than their quality. While existing treatments, such as assisted reproductive technologies, help with fertility preservation, they have limited success in truly reversing the aging process.
Excitingly, a new generation of experimental strategies is emerging. These include techniques like in vitro activation, which aims to stimulate dormant egg follicles; platelet-rich plasma therapy, utilizing growth factors from a patient’s own blood; and therapies involving stem cells and exosomes, which are tiny vesicles used for cell communication. Other innovative approaches involve mitochondrial replacement, where healthy mitochondria are used to replace damaged ones, and in vitro gametogenesis, which seeks to create eggs in a laboratory setting.
These cutting-edge strategies signal a significant shift in approach, moving beyond simply managing the decline in ovarian function to actively exploring ways to restore it. While promising, these methods are still in their early stages and require further rigorous research to confirm their safety and effectiveness.
Source: link to paper